Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23219692 | 1.00 | GNAI3 (0.31) | GNAI3GNAO1GNAI1 | |
| SCHEMBL24486076 | 0.86 | FDPS (0.33) | — | |
| SCHEMBL19251213 | 0.81 | GNAI3 (0.40) | GNAI3GNAO1GNAI1 | |
| SCHEMBL18976271 | 0.80 | GNAI3 (0.37) | GNAI3GNAO1GNAI1 | |
| SCHEMBL18976503 | 0.78 | GNAI3 (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL22962200 | 0.77 | NOS1 (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL24788378 | 0.77 | SPHK1 (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL26798425 | 0.75 | GNAI3 (0.31) | GNAI3GNAO1GNAI1 | |
| SCHEMBL23219791 | 0.75 | HTR7 (0.32) | — | |
| SCHEMBL20939984 | 0.73 | GNAI3 (0.33) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | GNAI3 133/4885GNAO1 544/4885GNAI1 61/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | GNAI3 111/4885GNAO1 361/4885GNAI1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.